Overview

Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of PBF-999 "After Multiple Oral Doses" in Healthy Volunteers

Status:
Terminated

Trial end date:
2016-05-01

Target enrollment:

Participant gender:

Summary

To assess the safety and tolerability of five doses of PBF-999 (160 mg and 320mg) after repeated (8 days) single daily oral dose administration in young male and female healthy subjects.

Phase:

Phase 1

Details

Lead Sponsor:

Palobiofarma SL

Collaborator:

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau